SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Jacqueline du Pré

PatientJacqueline Mary du Pré
Date of birth1998-01-26
IdentifiersMRN HR-ML039-SYN; SSN (made up) 000-39-7062
Document date2026-03-23
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Diagnosis visit: MRI and lumbar puncture results and the neurology consultation. [S]

History of Present Illness

Ms. du Pré returns two weeks after her first visit. MRI of the brain and spine three days after that visit showed lesions typical of multiple sclerosis in the brain and the spinal cord, including an enhancing lesion at C3 to C4 that explains her hands, and the lumbar puncture a week ago showed oligoclonal bands in the spinal fluid only. Aquaporin-4 antibody was negative. She was seen today by Dr. Lindgren-Achebe. The numbness and clumsiness in her fingers are no better; she has practiced for only a few minutes at a time this week and has cancelled two more concerts. The electric feeling down her back when she bends her head continues. She is tired by mid-afternoon. She asked what multiple sclerosis will mean for her playing, and whether she can still have children. [S]

ElementDetail
DiagnosisRelapsing-remitting multiple sclerosis, active: dissemination in space and time on MRI and CSF-specific oligoclonal bands
Tests since the first visitMRI of the brain and cervical and thoracic spine with gadolinium; lumbar puncture; aquaporin-4 antibody; HIV and syphilis serology
SymptomsNumb, clumsy fingers, worse on the left; Lhermitte's sign; fatigue
Her questionsWhether she will play again; whether she can have children; how treatment will fit around concerts and teaching

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired by mid-afternoon; no fever; weight steady
NeurologicalPositiveNumbness and clumsiness of the fingers; Lhermitte's sign; no weakness of the legs, imbalance or visual change
GenitourinaryNegativeNo urinary urgency or burning; last period three weeks ago
EyesNegativeNo blurred vision or pain on moving the eyes
MusculoskeletalNegativeNo back pain
PsychiatricPositiveFrightened and tearful about her playing; PHQ-9 7, GAD-7 6; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route2026-03-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-23Body height173cmS
2026-03-23Body weight63.4kgS
2026-03-23Body mass index (BMI) [Ratio]21.2kg/m2S
2026-03-23Systolic blood pressure114mm[Hg]S
2026-03-23Diastolic blood pressure72mm[Hg]S
2026-03-23Heart rate76/minS
2026-03-23Respiratory rate14/minS
2026-03-23Body temperature36.7CelS
2026-03-23Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-2325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma16ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientLowS
2026-03-23IgG [Mass/volume] in Serum or Plasma1080mg/dL700-1600 mg/dLNormalS
2026-03-23IgM [Mass/volume] in Serum or Plasma124mg/dL40-230 mg/dLNormalS
2026-03-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-03-23Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
2026-03-239-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]24.5sS
2026-03-239-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]31sS

Physical Exam

Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 63.4 kg; blood pressure 114/72, pulse 76
Cranial nervesNormal; no nystagmus; visual acuity and fields normal
NeurologicalReduced vibration and joint position sense in the fingers of both hands, worse on the left, with mild wandering of the left fingers when the eyes are closed; light touch reduced in the fingertips; finger and wrist strength 5 out of 5 except finger abduction 4+ on the left; brisk reflexes in the arms; Lhermitte's sign present; gait and balance normal. Nine-hole peg test 24.5 seconds right, 31.0 seconds left. EDSS 2.0
PsychiatricWarm and expressive; anxious; asks exact questions

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 2017 McDonald criteria and the 2024 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingMRI of the brain and cervical and thoracic spine with gadoliniumAt diagnosisUp to dateEleven typical brain lesions in periventricular, juxtacortical and infratentorial sites, one enhancing; enhancing C3 to C4 lesion and non-enhancing T7 lesion; central veins in most lesions
LaboratoryCerebrospinal fluid: oligoclonal bands, cell count, proteinAt diagnosis when it adds certaintyUp to dateSix CSF-specific oligoclonal bands; IgG index 0.86; white cells 6, protein 42 mg/dL
LaboratoryMimics: vitamin B12, TSH, HIV, syphilisAt diagnosisUp to dateB12 468 pg/mL and TSH 1.6 mIU/L at the first visit; HIV and syphilis negative
LaboratoryAquaporin-4 antibody (cell-based assay)When a myelitis or optic neuritis raises neuromyelitis optica spectrum disorderUp to dateNegative
LaboratoryMOG antibodyOnly when the picture suggests MOG antibody diseaseNot indicatedNo optic neuritis, long cord lesion or ADEM-like picture; typical MS lesions with central veins
LaboratoryJCV antibodyBefore choosing natalizumab, and every six months while on itUp to datePositive, index 1.4 (drawn with the lumbar puncture); natalizumab not chosen
LaboratoryHepatitis B (surface antigen, core antibody, surface antibody), varicella and measles immunityBefore anti-CD20 therapyUp to dateDrawn with the lumbar puncture: hepatitis B surface antigen and core antibody negative, surface antibody negative (not immune); varicella IgG positive; measles immune by two recorded doses
LaboratoryImmunoglobulins (IgG, IgM)At baseline and before each ocrelizumab doseCompleted todayIgG 1080 mg/dL, IgM 124 mg/dL
Laboratory25-hydroxyvitamin DAt diagnosisCompleted today16 ng/mL: deficient
LaboratoryPregnancy testBefore steroids and before each ocrelizumab doseCompleted todayUrine pregnancy test negative
Medication safetyInfection screen before high-dose steroidsBefore each steroid courseCompleted todayUrine dipstick negative; no fever
Medication safetyVaccinations before B-cell therapyInactivated vaccines at least two weeks before the first dose; live vaccines at least four weeks beforeCompleted todayPCV20, recombinant zoster dose 1 and hepatitis B dose 1 given today; no live vaccine needed
ExaminationHand function: nine-hole peg test, both handsAt diagnosis, after a relapse, and at each reviewCompleted today24.5 seconds right, 31.0 seconds left (typical for her age about 17 to 19 seconds)
ExaminationNeurological examination and EDSSAt diagnosis and at each reviewCompleted todaySensory loss in the fingers, mild left finger weakness, Lhermitte's sign; EDSS 2.0
ReferralOccupational therapyFor any problem with hand function or fatigueReferredAssessment booked for next week
SurveyMood and anxiety (PHQ-9, GAD-7)At diagnosis and at each reviewCompleted todayPHQ-9 7 (item 9 scored 0), GAD-7 6
Self-managementPregnancy planning and contraceptionAt diagnosis and at each reviewCompleted todayPregnancy is possible with multiple sclerosis; on ocrelizumab, conception is best planned a few months after a dose, with the neurologist; condoms for now
Self-managementWritten information and MS specialist nurseAt diagnosisCompleted todayWritten information given; nurse contact and relapse line

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine (PCV20), before B-cell therapy; Recombinant zoster vaccine, dose 1 of 2, before B-cell therapy; Hepatitis B vaccine (adjuvanted, two-dose series), dose 1, before B-cell therapy [S]

Guideline basis: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-173 (PMID 29275977) (2017); Montalban X, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24(10):850-865 (doi:10.1016/S1474-4422(25)00270-4) (2025); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019)

Follow-up: Methylprednisolone from tomorrow for 3 days; occupational therapy next week; ocrelizumab day 1 in three weeks. Review at the second half-dose. Call at once for new weakness, imbalance, loss of vision or bladder control. Next scheduled visit 2026-04-27: second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and work. [S]